Lowest-Rated StocksLowest-RatedNASDAQ:AMED Amedisys (AMED) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free AMED Stock Alerts $91.79 +0.63 (+0.69%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$91.00▼$91.8850-Day Range$90.40▼$94.5052-Week Range$73.10▼$96.44Volume144,548 shsAverage Volume197,102 shsMarket Capitalization$3.00 billionP/E RatioN/ADividend YieldN/APrice Target$97.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Amedisys alerts: Email Address Amedisys MarketRank™ Stock AnalysisAnalyst RatingHold2.13 Rating ScoreUpside/Downside6.2% Upside$97.50 Price TargetShort InterestBearish7.51% of Float Sold ShortDividend StrengthN/ASustainability-0.61Upright™ Environmental ScoreNews Sentiment0.80Based on 17 Articles This WeekInsider TradingN/AProj. Earnings Growth9.47%From $4.54 to $4.97 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.78 out of 5 starsMedical Sector416th out of 913 stocksHome Health Care Services Industry6th out of 8 stocks 1.1 Analyst's Opinion Consensus RatingAmedisys has received a consensus rating of Hold. The company's average rating score is 2.13, and is based on 1 buy rating, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageAmedisys has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.51% of the float of Amedisys has been sold short.Short Interest Ratio / Days to CoverAmedisys has a short interest ratio ("days to cover") of 8.7.Change versus previous monthShort interest in Amedisys has recently decreased by 4.02%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAmedisys does not currently pay a dividend.Dividend GrowthAmedisys does not have a long track record of dividend growth. Previous Next 5.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAmedisys has received a 82.47% net impact score from Upright. Amedisys seems to create the most significant positive value in categories "Jobs", "Meaning & joy", and "Taxes". The positive contribution in the "Meaning & joy" impact category is mostly driven by its "Private hospice care", "Private speech therapy services", and "Private occupational physiotherapy services" products. See details.Environmental SustainabilityThe Environmental Impact score for Amedisys is -0.61. Previous Next 2.7 News and Social Media Coverage News SentimentAmedisys has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Amedisys this week, compared to 4 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amedisys insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Amedisys is held by insiders.Percentage Held by Institutions94.36% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Amedisys are expected to grow by 9.47% in the coming year, from $4.54 to $4.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amedisys is -143.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amedisys is -143.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAmedisys has a PEG Ratio of 4.28. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmedisys has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Amedisys Stock (NASDAQ:AMED)Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients. The Hospice segment offers services that is designed to provide comfort and support for those who are dealing with a terminal illness, including cancer, heart disease, pulmonary disease, or Alzheimer's. The High Acuity Care offers essential elements of inpatient hospital, skilled nursing facility care, and palliative care to patients in their homes. Amedisys, Inc. was incorporated in 1982 and is headquartered in Baton Rouge, Louisiana.Read More AMED Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMED Stock News HeadlinesApril 27, 2024 | americanbankingnews.comAmedisys (NASDAQ:AMED) Earns "Neutral" Rating from Cantor FitzgeraldApril 27, 2024 | americanbankingnews.comQ2 2024 EPS Estimates for Amedisys, Inc. (NASDAQ:AMED) Lifted by William BlairApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 25, 2024 | finanznachrichten.deAmedisys, Inc.: Amedisys Reports First Quarter 2024 Financial ResultsApril 25, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Hold Rating on Amedisys (AMED)April 25, 2024 | sfgate.comAmedisys: Q1 Earnings SnapshotApril 25, 2024 | investorplace.comAMED Stock Earnings: Amedisys Beats EPS, Beats Revenue for Q1 2024April 24, 2024 | globenewswire.comAmedisys Reports First Quarter 2024 Financial ResultsApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.April 19, 2024 | msn.comDOJ case against UnitedHealth could take years to resolve, says BoAApril 19, 2024 | finance.yahoo.comInterim HealthCare Appoints New Clinical Quality LeaderApril 11, 2024 | msn.comImpact of aldehydes on DNA damage and agingApril 3, 2024 | finance.yahoo.comSurescripts exploring a sale: reportMarch 25, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Amedisys (AMED) and Masimo (MASI)March 25, 2024 | msn.comUnitedHealth's Takeover of Amedisys Expected to Close Despite Potential Regulatory Hurdles, RBC SaysMarch 20, 2024 | msn.comAmedisys dips amid report DOJ considering lawsuit to block UnitedHealth dealMarch 19, 2024 | reuters.comOregon's health authority reviewing UnitedHealth's acquisition of AmedisysFebruary 24, 2024 | finance.yahoo.comCAH Mar 2024 103.000 putFebruary 23, 2024 | finanznachrichten.deAmedisys, Inc.: Amedisys Reports Fourth Quarter and Year-End 2023 Financial ResultsFebruary 23, 2024 | uk.finance.yahoo.comQ4 2023 Blue Owl Capital Corp Earnings CallFebruary 22, 2024 | finance.yahoo.comAmedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to SayFebruary 21, 2024 | msn.comAmedisys (AMED) Q4 Earnings Lag EstimatesFebruary 21, 2024 | finance.yahoo.comAmedisys Reports Fourth Quarter and Year-End 2023 Financial ResultsFebruary 21, 2024 | finance.yahoo.comAmedisys Inc (AMED) Reports Mixed Results Amidst Merger TransactionsFebruary 21, 2024 | globenewswire.comAmedisys Reports Fourth Quarter and Year-End 2023 Financial ResultsFebruary 21, 2024 | finance.yahoo.comKain Capital-Backed PERA Holdings Hires CEO and CCOFebruary 18, 2024 | finance.yahoo.comAMED Mar 2024 95.000 putSee More Headlines Receive AMED Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amedisys and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/24/2024Today4/27/2024Next Earnings (Estimated)7/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Home health care services Sub-IndustryHealth Care Services Current SymbolNASDAQ:AMED CUSIP02343610 CIK896262 Webwww.amedisys.com Phone(225) 292-2031Fax225-292-8163Employees19,000Year Founded1982Price Target and Rating Average Stock Price Target$97.50 High Stock Price Target$101.00 Low Stock Price Target$81.00 Potential Upside/Downside+6.2%Consensus RatingHold Rating Score (0-4)2.13 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E Ratio20.22 P/E Growth4.28Net Income$-9,750,000.00 Net Margins-0.91% Pretax Margin1.77% Return on Equity13.00% Return on Assets7.01% Debt Debt-to-Equity Ratio0.32 Current Ratio1.05 Quick Ratio1.05 Sales & Book Value Annual Sales$2.24 billion Price / Sales1.34 Cash Flow$6.16 per share Price / Cash Flow14.90 Book Value$34.31 per share Price / Book2.68Miscellaneous Outstanding Shares32,670,000Free Float32,080,000Market Cap$3.00 billion OptionableOptionable Beta0.86 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Scott G. Ginn (Age 55)Executive VP, COO, CFO & Principal Financial Officer Comp: $659.94kMr. Michael P. North (Age 59)Chief Information Officer Comp: $442.38kMs. Denise Bohnert (Age 46)Chief Compliance Officer Comp: $399.72kMr. Nick Muscato (Age 38)Chief Strategy Officer Comp: $400.94kMr. Richard M. Ashworth (Age 49)President, CEO & Director Ms. Allyson GuidrozChief Accounting Officer & Principal Accounting OfficerMr. Pete HartleyCTO & Senior VP of Business Operations SystemsMs. Jennifer Guckert GriffinSenior VP, Deputy General Counsel, Corporate Secretary & Interim Chief Legal OfficerKendra KimmonsVP of Marketing & Communications & Media RelationsMr. Adam Holton (Age 53)Chief People Officer More ExecutivesKey CompetitorsLHC GroupNASDAQ:LHCGChemedNYSE:CHEBrightSpring Health ServicesNASDAQ:BTSGAddus HomeCareNASDAQ:ADUSAdaptHealthNASDAQ:AHCOView All CompetitorsInstitutional OwnershipEquitec Proprietary Markets LLCBought 1,200 shares on 4/26/2024Ownership: 0.000%Yousif Capital Management LLCSold 342 shares on 4/26/2024Ownership: 0.046%New York State Teachers Retirement SystemSold 4,200 shares on 4/25/2024Ownership: 0.106%Amalgamated BankBought 1,574 shares on 4/23/2024Ownership: 0.067%Louisiana State Employees Retirement SystemBought 200 shares on 4/23/2024Ownership: 0.029%View All Institutional Transactions AMED Stock Analysis - Frequently Asked Questions Should I buy or sell Amedisys stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares. View AMED analyst ratings or view top-rated stocks. What is Amedisys' stock price target for 2024? 8 brokers have issued 1 year price targets for Amedisys' shares. Their AMED share price targets range from $81.00 to $101.00. On average, they expect the company's share price to reach $97.50 in the next twelve months. This suggests a possible upside of 6.2% from the stock's current price. View analysts price targets for AMED or view top-rated stocks among Wall Street analysts. How have AMED shares performed in 2024? Amedisys' stock was trading at $95.06 at the beginning of 2024. Since then, AMED shares have decreased by 3.4% and is now trading at $91.79. View the best growth stocks for 2024 here. Are investors shorting Amedisys? Amedisys saw a decrease in short interest in March. As of March 31st, there was short interest totaling 2,490,000 shares, a decrease of 20.2% from the March 15th total of 3,120,000 shares. Based on an average trading volume of 291,300 shares, the short-interest ratio is presently 8.5 days. Currently, 7.8% of the shares of the company are sold short. View Amedisys' Short Interest. When is Amedisys' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024. View our AMED earnings forecast. How were Amedisys' earnings last quarter? Amedisys, Inc. (NASDAQ:AMED) issued its earnings results on Wednesday, April, 24th. The health services provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. The health services provider earned $571.41 million during the quarter, compared to analysts' expectations of $565.38 million. Amedisys had a negative net margin of 0.91% and a positive trailing twelve-month return on equity of 13.00%. Amedisys's revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.00 EPS. What ETFs hold Amedisys' stock? ETFs with the largest weight of Amedisys (NASDAQ:AMED) stock in their portfolio include First Trust Merger Arbitrage ETF (MARB), IQ Merger Arbitrage ETF (MNA), SPDR S&P Health Care Services ETF (XHS), SRH U.S. Quality ETF (SRHQ), AltShares Event-Driven ET (EVNT), AltShares Merger Arbitrage ETF (ARB), Sovereigns Capital Flourish Fund (SOVF) and Fundamentals First ETF (KNOW). What is Paul B. Kusserow's approval rating as Amedisys' CEO? 478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend. What other stocks do shareholders of Amedisys own? Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD). Who are Amedisys' major shareholders? Amedisys' stock is owned by many different retail and institutional investors. Top institutional shareholders include Leeward Investments LLC MA (0.31%), New York State Teachers Retirement System (0.11%), Bridge City Capital LLC (0.09%), Amalgamated Bank (0.07%), Equitec Proprietary Markets LLC (0.00%) and Yousif Capital Management LLC (0.05%). Insiders that own company stock include Bruce D Perkins, Christopher Gerard, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter and Scott G Ginn. View institutional ownership trends. How do I buy shares of Amedisys? Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AMED) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amedisys, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
